Restricting Patent Challenges Will Harm Small Businesses

After building momentum for weeks, congressional action on patent reform legislation is beginning to slow. The Senate Judiciary Committee has twice postponed markup of the bi-partisan PATENT Act in recent weeks. Reportedly, one reason behind the pause is a push by the pharmaceutical industry to include amendments that would limit the Patent and Trademark Office’s (PTO) authority to reevaluate the validity of issued patents at the request of third-parties that haven’t themselves been accused of infringement.

Read More